Transdermal Drug Delivery System Market

Hisamitsu Pharmaceuticals, Mylan and Novartis are leading players in Transdermal Drug Delivery Systems Market

The transdermal drug delivery systems market is projected to reach USD 7.1 billion by 2023 from an estimated USD 5.7 billion in 2018, at a CAGR of 4.5% during the forecast period of 2018 to 2023.  Market growth is largely driven by the global increase in the prevalence of chronic diseases. In addition, technological advancements in transdermal drug delivery systems are also expected to support market growth in the coming years.

Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), GlaxoSmithKline (UK), Abbvie (US), Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US) are the major players operating in the global transdermal drug delivery systems market. These players have adopted various growth strategies, such as product launches and enhancements; agreements, partnerships, mergers, and collaborations; acquisitions; and expansions to strengthen their presence in the global market. Product launches and partnerships have been the most widely adopted strategies by major players from 2015 to 2018. These strategies helped market players to offer innovate products and broaden their customer base.

In 2017, Hisamitsu Pharmaceutical (Japan), Mylan (US), Novartis (Switzerland), and Abbvie (US) together accounted for a share of ~55.0% of the transdermal drug delivery systems market.

To know about the assumptions considered for the study download the pdf brochure

Hisamitsu Pharmaceuticals dominated the transdermal drug delivery systems market in 2017. The company offers a wide range of products for the treatment of pain management. It offers transdermal patches for the treatment of pain under brand names such as Salonpas, MOHRUS TAPE, MOHRUS PAP, MOHRUS PAP XR, Estrana Tape, and Feitas. To maintain its leading position in the market, the company primarily focuses on expanding its product portfolio. For instance, the company launched Feitas, Z DICSAS, and NobiNobi Salonship FH in 2017. Moreover, the company is focusing on agreements to expand its customer base. For instance, in 2018, the company signed an agreement in the category of external pain relief products with the Tokyo Organizing Committee of the Olympic and Paralympic Games (2020).

Mylan is one of the leading players operating in the transdermal drug delivery systems market. The company offers transdermal patches for birth control under the brand name Xulane. Mylan has a robust worldwide commercial presence, including the leading position in the US, Australia, and France. The company has a portfolio of more than 7,500 marketed generic, branded, and OTC products. Also, it owns 12 manufacturing and distribution facilities in the US and has its production and distribution facilities in 11 countries, including India, Australia, Japan, Ireland, Hungary, and France.

Novartis is one of the leading players operating in the transdermal drug delivery systems market. The company offers transdermal patches for the treatment of all stages of Alzheimer's disease under the brand name Exelon. Novartis has a presence in over 155 countries across North America, Europe, Asia, Africa, and Latin America. The company offers drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, and neurological disorders through its Innovative Medicines segment. In order to strengthen its position in the market, the company is strategically focusing on the development of new products by investing in research and development. In 2017, Novartis invested USD 9.0 billion on R&D. The strong focus of the company on the development of new and advanced products is expected to help it sustain its strong position in the transdermal drug delivery systems market in the coming years.

Related Reports:

Transdermal Drug Delivery System Market by Type (Patches and Semisolid formulations), Applications (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Diseases), End User, and Region - Global Forecast to 2023

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Transdermal Drug Delivery System Market Size,  Share & Growth Report
Report Code
PH 7546
RI Published ON
1/8/2019
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

SEND ME A FREE SAMPLE
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status